Trials / Not Yet Recruiting
Not Yet RecruitingNCT06361979
SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases
A Single-arm, Exploratory Clinical Study of SHR-A1811 Combined With Bevacizumab in the Treatment of HER2-positive Breast Cancer With Brain Metastases
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Huihua Xiong · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aimed to evaluate the use of SHR-A1811 and bevacizumab in HER2-positive Breast Cancer with brain metastases
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1811 | SHR-A1811: intravenous |
| DRUG | Bevacizumab | Bevacizumab:intravenous |
Timeline
- Start date
- 2024-05-01
- Primary completion
- 2025-05-01
- Completion
- 2026-05-01
- First posted
- 2024-04-12
- Last updated
- 2024-04-12
Source: ClinicalTrials.gov record NCT06361979. Inclusion in this directory is not an endorsement.